United States - English - NLM (National Library of Medicine)

rebel distributors corp - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v) - fexofenadine hydrochloride 180 mg - fexofenadine hydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. fexofenadine hydrochloride tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 of age and older . fexofenadine hydrochloride tablets are contraindicated in patients with known hypersensitivity to fexofenadine and any of the ingredients of fexofenadine hydrochloride. rare cases of hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnea, flushing and systemic anaphylaxis have been reported. teratogenic effects: pregnancy category c. there was no evidence of teratogenicity in rats or rabbits at oral doses of terfenadine up to 300 mg/kg (which led to fexofenadine exposures that were approximately 4 and 30 times, respectively, the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on c

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fexofenadine hydrochloride 180mg; fexofenadine hydrochloride 180mg - film coated tablet - 180 mg - active: fexofenadine hydrochloride 180mg excipient: croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose opacode black s-1-8152hv povidone purified talc purified water titanium dioxide active: fexofenadine hydrochloride 180mg excipient: croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose opacode black s-1-27794 povidone purified talc purified water titanium dioxide

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v) - fexofenadine hydrochloride 180 mg - fexofenadine hydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older. fexofenadine hydrochloride tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. fexofenadine hydrochloride tablets are contraindicated in patients with known hypersensitivity to fexofenadine and any of the ingredients of fexofenadine hydrochloride tablets. rare cases of hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnea, flushing and systemic anaphylaxis have been reported. pregnancy category c. there was no evidence of teratogenicity in rats or rabbits at oral doses of terfenadine up to 300 mg/kg (which led to fexofenadine exposures that were approximately 4 and 30 times, respectively, the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparis

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v) - fexofenadine hydrochloride 60 mg - fexofenadine hydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older. fexofenadine hydrochloride tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. fexofenadine hydrochloride tablets are contraindicated in patients with known hypersensitivity to fexofenadine and any of the ingredients of fexofenadine hydrochloride tablets. rare cases of hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnea, flushing and systemic anaphylaxis have been reported. pregnancy category c. there was no evidence of teratogenicity in rats or rabbits at oral doses of terfenadine up to 300 mg/kg (which led to fexofenadine exposures that were approximately 4 and 30 times, respectively, the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparis

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v) - fexofenadine hydrochloride 30 mg - fexofenadine hydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. fexofenadine hydrochloride tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 of age and older . fexofenadine hydrochloride tablets are contraindicated in patients with known hypersensitivity to fexofenadine and any of the ingredients of fexofenadine hydrochloride. rare cases of hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnea, flushing and systemic anaphylaxis have been reported. teratogenic effects: pregnancy category c. there was no evidence of teratogenicity in rats or rabbits at oral doses of terfenadine up to 300 mg/kg (which led to fexofenadine exposures that were approximately 4 and 30 times, respectively, the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on c

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v) - fexofenadine hydrochloride 30 mg - fexofenadine hydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. symptoms treated effectively were sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes. fexofenadine hydrochloride tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. it significantly reduces pruritus and the number of wheals. fexofenadine hydrochloride tablets are contraindicated in patients with known hypersensitivity to any of its ingredients.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v) - fexofenadine hydrochloride 60 mg - fexofenadine hydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. symptoms treated effectively were sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes. fexofenadine hydrochloride tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. it significantly reduces pruritus and the number of wheals. fexofenadine hydrochloride tablets are contraindicated in patients with known hypersensitivity to any of its ingredients.

United States - English - NLM (National Library of Medicine)

dr.reddy's laboratories limited - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - fexofenadine hcl 180 mg and pseudoephedrine hcl 240 mg extended-release tablets (24 hour formulation) are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion.  fexofenadine hcl 180 mg and pseudoephedrine hcl 240 mg extended-release tablets (24 hour formulation) should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology ). fexofenadine hcl 180 mg and pseudoephedrine hcl 240 mg extended-release tablets (24 hour formulation) are contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, fexofenadine hcl 180 mg and pseudoephedrine hcl  240 mg extended-release tablets (24 hour formulation) are contrai

Ireland - English - HPRA (Health Products Regulatory Authority)

azure pharmaceuticals ltd - fexofenadine hydrochloride - film-coated tablet - 180 milligram(s) - fexofenadine

United States - English - NLM (National Library of Medicine)

stat rx usa llc - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - allegra-d 24 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 24 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 24 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 24 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe co